- In late March 2026, Zoetis Inc. participated in the World Vaccine Congress in Washington, while also scheduling a May webcast and call to review its first-quarter 2026 financial results with investors.
- A separate development saw Bristol Gate Capital Partners exit its long-held Zoetis position, citing slowing dividend growth, setbacks for key osteoarthritis drug Librela, and rising competitive pressures in core product categories.
- Against this backdrop, we’ll now examine how concerns over slowing dividend growth may influence Zoetis’s existing investment narrative.
AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Zoetis Investment Narrative Recap
To be comfortable owning Zoetis today, you have to believe in the long-term demand for pet and livestock health products and the company’s ability to keep innovating in core franchises like osteoarthritis pain, parasiticides and dermatology. The Bristol Gate exit and its focus on slowing dividend growth and Librela setbacks highlight that the near term catalyst around confidence in Zoetis’s growth profile is tied closely to execution in these key products, while competitive pressure remains the most immediate business risk.
Against that backdrop, the Q1 2026 earnings call and webcast scheduled for May now looks particularly important. With Bristol Gate pointing to a reduced dividend increase and guidance reset, this update is where investors can reassess how management frames growth, capital returns and competitive dynamics in light of Librela’s challenges and rising rivalry in core categories, and whether the current guidance range still feels appropriately supported by underlying business trends.
Yet beneath Zoetis’s long track record, investors should be aware that slowing dividend growth amid intensifying competition could signal...
Read the full narrative on Zoetis (it's free!)
Zoetis’ narrative projects $10.9 billion revenue and $3.2 billion earnings by 2028. This requires 5.2% yearly revenue growth and a roughly $0.6 billion earnings increase from $2.6 billion today.
Uncover how Zoetis' forecasts yield a $151.00 fair value, a 29% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already baking in slower progress, with revenue of about US$10.6 billion and earnings of roughly US$2.9 billion by 2028, so if you worry about regulatory pressure on pricing and margins, this more cautious view shows how different your conclusions can be from consensus and why it is worth comparing several possible paths for Zoetis after setbacks like the Librela controversy.
Explore 9 other fair value estimates on Zoetis - why the stock might be worth just $130.00!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Zoetis research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.
No Opportunity In Zoetis?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com